SIGNIFICANCE OF OSTEOPONTIN FOR PREDICTING AGGRESSIVENESS OF PROSTATE CANCER

Authors

  • N. Lukianova R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
  • Т. Zadvornyi R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
  • Т. Borikun R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
  • О. Mushii R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
  • А. Pavlova R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
  • А. Tymoshenko R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
  • Е. Stakhovskyi The State Non-Profit Enterprise "National Cancer Institute" of the Ministry of Health of Ukraine, Kyiv, Ukraine
  • I. Vitruk The State Non-Profit Enterprise "National Cancer Institute" of the Ministry of Health of Ukraine, Kyiv, Ukraine
  • V. Сhekhun R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine

DOI:

https://doi.org/10.15407/exp-oncology.2023.03.312

Keywords:

prostate cancer, osteopontin, prognosis, survival

Abstract

Background. Effective prediction of the course of prostate cancer (PCa) and the stratification of treatment tactics largely depend on the use of prognostic markers that reflect the molecular and biological features of tumors. In view of the important role of matricellular proteins in the modulation of the growing tumor and metastasis of the hormone-dependent neoplasms, the aim of the work was to study the expression of osteopontin (OPN) at the protein and mRNA levels in the PCa tissue in order to assess the significance of this protein for predicting the aggressiveness of PCa. Materials and Methods. The work is based on the analysis of the results of the examination and treatment of 83 patients with PCa of stages II—IV. The study of OPN expression at the level of mRNA and protein in the PCa tissue was carried out using methods of the real time polymerase chain reaction and immunohistochemistry, respectively. Results. The OPN expression in the PCa tissue was 1.6 times (p < 0.05) higher in patients with regional lymph node metastases compared to patients without metastases. In patients with a Gleason score of < 7, the OPN expression in the tumor tissue was 1.4 times lower (p < 0.05) than in patients with poorly differentiated PCa. In patients with a high risk of tumor progression, the OPN expression level was 1.4 and 2.1 times higher (p < 0.05) compared to patients with a moderate and low risk of PCa progression. The patients with a high OPN expression level in the PCa tissue had significantly decreased 2-year recurrence-free survival rate (by 25%). Conclusions. The obtained results indicate the expediency of using OPN expression indicators in the tumor tissue to predict the PCa aggressiveness and assess the risk of its recurrence.

References

Munteanu VC, Munteanu RA, Gulei D, et al. PSA based biomarkers, imagistic techniques and combined tests for a better diagnostic of localized prostate cancer. Diagnostics. 2020;10:806. https://doi.org/10.3390/diagnos- tics10100806

Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol. 2015;26:848-864. https://doi.org/10.1093/annonc/mdu525

Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA. 2014;311:1143-1149. https://doi.org/ 10.1001/jama.2014.2085

Pomerantz MM, Werner L, Xie W, et al. Association of prostate cancer risk loci with disease aggressiveness and prostate cancer–specific mortality. Сancer Prev Res (Phila). 2011;4: 719-728. https://doi.org/10.1158/1940-6207. CAPR-10-0292

Bhavsar T, McCue P, Birbe R. Moleculardiagnosisofprostatecancer: areweuptoage? Semin Oncol. 2013;40(3):259- 275. https://doi.org/10.1053/j.seminoncol.2013.04.002

Kohaar I, Petrovics G, Srivastava S. A rich array of prostate cancer molecular biomarkers: opportunities and challenges. Int J Mol Sci. 2019;20:1813; https://doi.org/10.3390/ijms20081813

Pentyala S, Whyard T, Pentyala S, et al. Prostate cancer markers: An update (review). Biomed Rep. 2016;4:263- 268. doi: 10.3892/br.2016.586

Li X, Liu Y, Wu B, et al. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis. Oncol Rep. 2014;32(6):2605-2611. https://doi.org/10.3892/or.2014.3511

Pang X, Gong K, Zhang X, et al. Osteopontin as a multifaceted driver of bone metastasis and drug resistance.

Pharmacol Res. 2019;144:235-244. https://doi.org/10.1016/j.phrs.2019.04.030

Forootan SS, Foster CS, Aachi VR, et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer. 2006;118(9):2255-2261. https://doi.org/10.1002/ijc.21619

Gupta A, Zhou CQ, Chellaiah MA. Osteopontin and MMP9: associations with VEGF expression/secretion and angiogenesis in PC3 prostate cancer cells. Cancers. 2013;5:617-638. https://doi.org/10.3390/cancers5020617

Zadvornyi T, Lukianova N, Borikun T, et al. Expression of osteopontin and osteonectin in breast and prostate cancer cells with different sensitivity to doxorubicin. Exp Oncol. 2022;44:107-112. https://doi.org/10.32471/exp- oncology.2312-8852.vol-44-no-2.17886

Lukianova N, Zadvornyi T, Kashuba E, et al. Expression of markers of bone tissue remodeling in breast cancer and prostate cancer cells in vitro. Exp Oncol. 2022;44:39-46. https://doi.org/10.32471/exp-oncology.2312-8852. vol-44-no-1.17354

Tilli TM, Mello KD, Ferreira LB, et al. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumor- igenic roles in prostate cancer cells. Prostate. 2012;72:1688-1699. https://doi.org/10.1002/pros.22523

Nakamura KD, Tilli TM, Wanderley JL, et al. Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells. Tumour Biol. 2016;37:2655-2663. https://doi.org/10.1007/s13277-015-4095-6

Butti R, Kumar TV, Nimma R, et al. Osteopontin signaling in shaping tumor microenvironment conducive to malignant progression. In: Birbrair, A. (eds) Tumor Microenvironment. Advances in Experimental Medicine and Biology. 2021;1329:419-441. Springer, Cham. https://doi.org/10.1007/978-3-030-73119-9_20

McClelland RA, Wilson D, Leake R, et al. A multicentre study into the reliability of steroid receptor immu- nocytochemical assay quantification. Eur J Cancer Clin Oncol. 1991;27:711-715. https://doi.org/10.1016/0277- 5379(91)90171-9

Zhang JD, Ruschhaupt M, Biczok R. ddCt method for qRT–PCR data analysis. Citeseer. 2013;48:346-356.

Mottet N, Cornford P, van den Bergh RCN, et al. EAU – EANM – ESTRO – ESUR – ISUP – SIOG guidelines on prostate cancer. Update 2021. Available at: http://uroweb.org/guideline/prostate-cancer/

Heo YJ, Hwa C, Lee GH, et al. Integrative multi-omics approaches in cancer research: from biological networks to clinical subtypes. Mol Cells. 2021;44:433-443. https://doi.org/10.14348/molcells.2021.0042

Yeatman TJ, Chambers AF. Osteopontin and colon cancer progression. Clin Exp Metastasis. 2003;20:85-90. https://doi.org/10.1023/a:1022502805474

Junaid A, Moon MC, Harding GE, Zahradka P. Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. Am J Physiol Cell Physiol. 2007;292:919-926. https://doi.org/10.1152/ajpcell.00477.2006

Lin J, Myers AL, Wang Z, et al. Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma. Oncotarget. 2015;6:22239-22257. https://doi.org/10.18632/onco- target.4161

Kariya Y, Kariya Y. Osteopontin in cancer: mechanisms and therapeutic targets. Int J Transl Med. 2022; 2:419-447. https://doi.org/10.3390/ijtm2030033

Weber GF, Lett GS, Haubein NC. Categorical meta-analysis of osteopontin as a clinical cancer marker. Oncol Rep. 2011;25:433-441. https://doi.org/10.3892/or.2010.1106

Lamort A-S, Giopanou I, Psallidas I, Stathopoulos GT. Osteopontin as a link between inflammation and cancer: the thorax in the spotlight. Cells. 2019;8:815. https://doi.org/10.3390/cells8080815

Hao C, Cui Y, Owen S, et al. Human osteopontin: potential clinical applications in cancer (Review). Int J Mol Med. 2017;39:1327-1337. https://doi.org/10.3892/ijmm.2017.2964

Weber G, Lett G, Haubein N. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer.

;103:861-869. doi: 10.1038/sj.bjc.6605834

Robertson BW, Bonsal L, Chellaiah MA. Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells. Mol Cancer. 2010;9:1-10. https://doi.org/10.1186/1476-4598-9-260

Kurisetty VV, Johnston PG, Johnston N, et al. RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin. Oncogene. 2008;27:7139-7149. https://doi.org/10.1038/onc.2008.325

Desai B, Ma T, Chellaiah MA. Invadopodia and matrix degradation, a new property of prostate cancer cells during migration and invasion. J Biol Chem. 2008;283:13856-13866. https://doi.org/10.1074/jbc.M709401200

Downloads

Published

28.12.2023

How to Cite

Lukianova, N., Zadvornyi Т., Borikun Т., Mushii О., Pavlova А., Tymoshenko А., … Сhekhun V. (2023). SIGNIFICANCE OF OSTEOPONTIN FOR PREDICTING AGGRESSIVENESS OF PROSTATE CANCER. Experimental Oncology, 45(3), 312–321. https://doi.org/10.15407/exp-oncology.2023.03.312

Issue

Vol. 45 No. 3 (2023): Experimental Oncology

Section

Original contributions

License

Copyright (c) 2023 Experimental Oncology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Most read articles by the same author(s)